Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

Launched by FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU · Jan 28, 2010

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Between 18 and 80 years old.
• • With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image.
• • No esophageal varices (or with small varices without red signs) in a recent videogastroscophy (\<3 months before randomization).
• • Absence of ascites demonstrated by a recent ultrasound (\<3 months before the randomization).
• • informed consent
• Exclusion Criteria:
• • previous decompensation of liver cirrhosis associated with portal hypertension.
• • GPVH \<10 mmHg.
• • Portal axis thrombosis affecting the portal trunk or main hepatic branches, or the splenic or mesenteric vein.
• • Hepatocellular carcinoma demonstrated by two imaging tests.
• • Bilirubin\> 3 mg / dl (or\> 50 micromol / l), platelets \<30 x10E9/lo Quick \<30%.
• • Presence of renal insufficiency (serum creatinine\> 2 mg / dl or\> 200 micromol / l).
• • Any comorbidity involving a therapeutic limitation and / or a prognosis of life \<12 months.
• • Absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis aortic A-V block, intermittent claudication, severe psychosis, bronchial asthma)
• • Hypersensitivity to β-blockers.
• • Pregnancy or lactation.
• • To receive anticoagulant treatment.
• • Past treatment with nitrated or β-blockers in the two weeks prior inclusion.
• • Cirrhosis C virus active antiviral therapy.